Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol in Perioperative Resectable Gastrointestinal Tumors
NCT06775080Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of propranolol in gastric cancer (GC) and colorectal cancer (CRC) (2 arms), sponsored by Huashan Hospital. Primary endpoints: Anxiety Depression Scale Scores at 2 years, Heart Rate at 24 days and 8 more. Started Dec 2024; status: recruiting.
02
Drugs
propranolol
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06775080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775080.